Therapeutic options for HIV-associated lymphomas

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 15, 2010, Pages 2471-2481

  Spina, Michele ^a   Gloghini, Annunziata ^b   Tirelli, Umberto ^a   Carbone, Antonino ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

AIDS related lymphomas; HIV associated lymphomas; KSHV HHV8 associated lymphomas; Therapeutic options

Indexed keywords

BORTEZOMIB; OFATUMUMAB; RITUXIMAB;

BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG BINDING; HEALTH CARE FACILITY; HIV ASSOCIATED LYMPHOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LARGE CELL LYMPHOMA; LYMPHOMA; NONHODGKIN LYMPHOMA; PATHOLOGY; PLASMABLASTIC LYMPHOMA; PRIMARY EFFUSION LYMPHOMA; PROGNOSIS; REVIEW; SALVAGE THERAPY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BORONIC ACIDS; EPSTEIN-BARR VIRUS INFECTIONS; HIV INFECTIONS; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, LARGE B-CELL, DIFFUSE; PYRAZINES; TREATMENT OUTCOME;

EID: 77957033810     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.502528     Document Type: Review

References (93)

1. Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998;351:1833-1839
2. Levine AM. Acquired immunodeficiency syndrome-related lymphoma: clinical aspects. Semin Oncol 2000;27:442-453
3. IARC monographs on the evaluation of carcinogenic risks to humans. Human immunodeficiency viruses and human T-cell lymphotrophic viruses. Volume 67. International Agency for Research on Cancer/World Health Organization, Lyon; 1996
4. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposis sarcoma. Science 1994;266:1865-1869
5. Raphael M, Said J, Borisch B, et al. Lymphomas associated with HIV infection. In: Swerdlow SH, Campo E, Harris NL, et al., editors, World Health Organization classification of tumours, pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon; 2008. p. 340-342
6. Carbone A, Gloghini A. AIDS-related lymphomas: from pathogenesis to pathology. Br J Haematol 2005;130:662-670
7. Cesarman E, Chang Y, Moore PS, et al. Kaposis sarcoma-associated herpesvirus-like DNA sequences are present in AIDS-related body cavity-based lymphoma. N Engl J Med 1995;332:1186-1191
8. Chadburn A, Hyjek E, Mathew S, et al. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol 2004;28:1401-1416
9. Carbone A, Gloghini A, Vaccher E, et al. Kaposis sarcoma-associated herpesvirus/ human herpesvirus type 8-positive solid lymphomas. A tissue-based variant of primary effusion lymphoma. J Mol Diagn 2005;7:17-27
10. Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997;89:1413-1420
11. Carbone A, Gaidano G, Gloghini A, et al. AIDS-related plasmablastic lymphomas of the oral cavity and jaws: a diagnostic dilemma. Ann Otol Rhinol Laryngol 1999;108:95-99
12. Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 2000;95:1406-1412
13. Carbone A, Cesarman E, Spina M, et al. HIV-associated lymphomas and gamma-herpesviruses. Blood 2009;113:1213-1224
14. Cesarman E, Knowles DM. The role of Kaposis sarcoma-associated herpesvirus (KSHV/HHV-8) in lymphoproliferative diseases. Semin Cancer Biol 1999;9:165-174
15. Carbone A, Gloghini A. KSHV/HHV8-associated lymphomas. Br J Haematol 2008;140:13-24
16. Capello D, Vitolo U, Pasqualucci L, et al. Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. Blood 2000;95:651-659
17. Carbone A, Gaidano G, Gloghini A, et al. Differential expression of BCl-6, CD138/syndecan-1 and EBV-encoded latent membrane protein-1 identifies distinct histogenetic pathways of AIDS-related non-Hodgkins lymphomas. Blood 1998;91:747-755
18. Carbone A, Gloghini A, Larocca LM, et al. Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subset of human immunodeficiency virus-related lymphomas. Blood 2001;97:744-751
19. Cattoretti G, Chang CC, Cechova K, et al. BCL-6 protein is expressed in germinal-center B cells. Blood 1995;86:45-53
20. Gaidano G, Carbone A. MUM1. A step ahead toward the understanding of lymphoma histogenesis. Leukemia 2000;14:449-456
21. Pasqualucci L, Migliazza A, Fracchiolla N, et al. BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. Proc Natl Acad Sci USA 1998;95:11816-11821
22. Shen HM, Peters A, Baron B, et al. Mutation of BCL-6 gene in normal B-cells by the process of somatic hypermutation of Ig genes. Science 1998;280:1750-1752
23. Vaccher E, Spina M, Talamini R, et al. Improvement of systemic Human Immunodeficiency virus-related non-Hodgkins lymphoma outcome in the era of highly active antiretroviral therapy. Clin Infect Dis 2003;37:1556-1564
24. Vaccher E, Tirelli U, Spina M, et al. Age and serum lactate dehydrogenase level are independent prognostic factors in HIV-related non-Hodgkins lymphoma: a single institution study of 96 patients. J Clin Oncol 1996;14:2217-2233
25. Tirelli U, Spina M, Vaccher E, et al. Clinical evaluation of 451 patients with HIV related non-Hodgkins lymphoma: experience of the Italian Cooperative Group on AIDS and Tumors (GICAT). Leuk Lymphoma 1995;20:91-96
26. Sparano JA. Clinical aspects and management of AIDS-related lymphoma. Eur J Cancer 2001;37:1296-1305
27. Spina M, Carbone A, Vaccher E, et al. Outcome in patients with non-Hodgkin lymphoma and with or without human immunodeficiency virus infection. Clin Infect Dis 2004;38:142-144
28. Kaplan LD, Straus DJ, Testa MA, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkins lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997;336:1641-1648
29. Mounier N, Spina M, Gabarre J, et al. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood 2006;107:3832-3840
30. Sparano JA, Lee S, Chen MG, et al. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkins lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). J Clin Oncol 2004;22:1491-1500
31. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003;101:4653-4659
32. Toffoli G, Corona G, Cattarossi G, et al. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkins lymphoma. Ann Oncol 2004;15:1805-1809
33. Sparano JA, Lee JY, Kaplan LD, et al. Rituximab plus concurrent EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkins lymphoma. Blood 2010;115:3008-3016
34. Bohlius J, Schmidlin K, Costagliola D, et al. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS 2009;23:2029-2037
35. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242
36. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127
37. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-391
38. Spina M, Jaeger U, Sparano JA, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide (R-CDE) in HIV-associated non-Hodgkins lymphoma: pooled results from three phase II trials. Blood 2005;105:1891-1897
39. Spina M, Simonelli C, Vaccher E, et al. Long-term follow-up of rituxiamb plus infusional cyclophosphamide, doxorubicin, and etoposide (CDE) in combination with HAART in HIV-related non-Hodgkins lymphomas (NHL) [abstract C001]. Proceedings of the 42nd National Conference of the Italian Society of Haematology (SIE), 18 - 21 October 2009, Milan, Italy. Haematologica 2009;94(Suppl 4):7
40. Boue F, Gabarre J, Gisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkins lymphoma. J Clin Oncol 2006;24:4123-4128
41. Ribera JM, Oriol A, Morgades M, et al. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Hematol 2008;140:411-419
42. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial. Blood 2005;106:1538-1543
43. Gutierrez M, Chabner BA, Pearson D, et al. Role of a doxorubicin- containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol 2000;18:3633-3642
44. Lai GM, Chen YN, Mickley LA, et al. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer 1991;49:696-703
45. Lim ST, Karim R, Nathwani BN, et al. AIDS-related Burkitts lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol 2005;23:4430-4438
46. Spina M, Simonelli C, Talamini R, Tirelli U. Patients with HIV with Burkitts lymphoma have a worse outcome than those with diffuse large-cell lymphoma also in the highly active antiretroviral therapy era. J Clin Oncol 2005;23:8132-8133
47. Wang ES, Straus DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 2003;98:1196-1205
48. Oriol A, Ribera JM, Esteve J, et al. Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. Haematologica 2003;88:445-453
49. Oriol A, Ribera JM, Bergua J, et al. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer 2008;113:117-125
50. Boulanger E, Gerard L, Gabarre J, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 2005;23:4372-4380
51. Weiss R, Mitrou P, Arasteh K, et al. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival - results of the German Multicenter Trial. Cancer 2006;106:1560-1568
52. Simonelli C, Spina M, Cinelli R, et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol 2003;21:3948-3954
53. Chen YB, Rahemtullah A, Hochberg E. Primary effusion lymphoma. Oncologist 2007;12:569-576
54. Spina M, Gaidano G, Carbone A, et al. Highly active antiretroviral therapy in human herpesvirus-8-related body-cavity-based lymphoma. AIDS 1998;12:955-956 (Pubitemid 28241413)
55. Won JH, Han SH, Bae SB, et al. Successful eradication of relapsed primary effusion lymphoma with high-dose chemotherapy and autologous stem cell transplantation in a patient seronegative for human immunodeficiency virus. Int J Hematol 2006;83:328-330
56. Boulanger E, Daniel MT, Agbalika F, et al. Combined chemotherapy including high-dose methotrexate in KSHV/ HHV8-associated primary effusion lymphoma. Am J Hematol 2003;73:143-148
57. Halfdanarson TR, Markovic SN, Kalokhe U, Luppi M. A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy. Ann Oncol 2006;17:1849-1850
58. Hocqueloux L, Agbalika F, Oksenhendler E, Molina JM. Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS 2001;15:280-282
59. Luppi M, Trovato R, Barozzi P, et al. Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir. Leukemia 2005;19:473-476
60. An J, Sun Y, Fisher M, et al. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia 2004;18:1699-1704
61. Siddiqi T, Joyce RM. A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab. Clin Lymphoma Myeloma 2008;8:300-304
62. Klass CM, Krug LT, Pozharskaya VP, et al. The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production. Blood 2005;105:4028-4034
63. Riedel DJ, Gonzalez-Cuyar F, Zhao XF, et al. Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection. Lancet Infect Dis 2008;8:261-267
64. Schichman SA, McClure R, Schaefer RF, Mehta P. HIV and plasmablastic lymphoma manifesting in sinus, testicles, and bones: a further expansion of the disease spectrum. Am J Hematol 2004;77:291-295
65. Nasta SD, Carrum GM, Shahab I, et al. Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy. Leuk Lymphoma 2002;43:423-426
66. Lester R, Li C, Phillips P, et al. Improved outcome of human immunodeficiency virus-associated plasmablastic lymphoma of the oral cavity in the era of highly active antiretroviral therapy: a report of two cases. Leuk Lymphoma 2004;45:1881-1885
67. Armstrong R, Bradrick J, Liu YC. Spontaneous regression of an HIV-associated plasmablastic lymphoma in the oral cavity: a case report. J Oral Maxillofac Surg 2007;65:1361-1364
68. Panos G, Karveli EA, Nikolatou O, et al. Prolonged survival of an HIV-infected patient with plasmablastic lymphoma of the oral cavity. Am J Hematol 2007;82:761-765
69. Spina M, Vaccher E, Juzbasic S, et al. Human immunodeficiency virus-related non-Hodgkin lymphoma: activity of infusional cyclophosphamide, doxorubicin and etoposide as second-line chemotherapy in 40 patients. Cancer 2001;1:200-206
70. Gabarre J, Marcelin AG, Azar N. High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. Haematologica 2004;89:1100-1108
71. Krishnan AY, Molina A, Zaia J, et al. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood 2005;105:874-878
72. Re A, Cattaneo C, Michieli M, et al. High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. J Clin Oncol 2003;21:4423-4427
73. Díez-Martín JL, Balsalobre P, Re A, et al. Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood 2009;113:6011-6014
74. Balsalobre P, Díez-Martín JL, Re A, et al. Autologous stem-cell transplantation in patients with HIV-related lymphoma. J Clin Oncol 2009;27:2192-2198
75. Re A, Michieli M, Casari S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood 2009;114:1306-1313
76. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362-371
77. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104:1793-1800
78. Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008;111:5486-5495
79. Hagenbeek A, Fayad L, Delwail V, et al. Evaluation of ofatumumab, a novel human CD20 monoclonal antibody, as single agent therapy in rituximab-refractory follicular lymphoma [abstract 935]. Blood 2009;114:385-386
80. Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008;111:1094-1100
81. Wierda WG, Kipps TJ, Durig J, et al. Ofatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): results from a randomized, multicenter, international, two-dose, parallel group, phase II trial [abstract 207]. Blood 2009;114:90
82. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-2622
83. Teicher BA, Ara G, Herbst R, et al. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999;5:2638-2645
84. Blum KA, Baiocchi RA, Alinari L, et al. A phase II trial of induction plus maintenance rituximab and bortezomib in patients with relapsed/refractory mantle cell (MCL) and follicular (FL) non-Hodgkins lymphoma. ASH Annual Meeting Abstracts. Blood 2008;112:abstract 3053
85. Moosmann PR, Heizmann M, Kotrubczik N, et al. Weekly treatment with a combination of bendamustine and bortezomib in relapsed or refractory indolent non-Hodgkins lymphoma: a single-center phase 1/2 study. ASH Annual Meeting Abstracts. Blood 2008;112:abstract 1574
86. David KA, Smith MR, Lossos IS, et al. A phase II trial of combination bortezomib (Velcade-) and rituximab for untreated high tumor burden indolent non-Hodgkin lymphoma (NHL). ASH Annual Meeting Abstracts. Blood 2008;112:abstract 2004
87. Di Bella N, Taetle R, Kolibaba K, et al. Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood 2010;115:475-480
88. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006;24:5343-5349
89. Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008;26:1544-1552
90. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-2142
91. Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkins lymphoma. J Clin Oncol 2008;26:4952-4957
92. Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkins lymphoma. J Clin Oncol 2009;27:5404-5409
93. Tulpule A, Espina BM, Berman N, et al. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkins lymphoma. Clin Lymphoma Myeloma 2006;7:59-64